Christina T. Loguidice


Combinations Gain Momentum as First-Line Treatments for Unresectable Hepatocellular Carcinoma

May 25th 2022

A panel of hepatobiliary tumor experts discuss several pivotal phase 3 clinical trials examining combination approaches that have expanded or are anticipated to expand the treatment armamentarium for treatment-naïve patients with unresectable hepatocellular carcinoma.

Targeted Treatment Boom Reshapes Differentiated Thyroid Cancer Landscape

April 18th 2022

Marcia S. Brose, MD, PhD, FASCO, and a panel of thyroid cancer experts share their insights into the evolving treatment landscape, including the use of VEGF receptor inhibitors and some of the precision medicine treatments now identified for molecularly selected subsets of patients with differentiated thyroid cancer, such as BRAF, RET, and TRK inhibitors.

Experts Survey Treatment Variations for Resectable NSCLC in Asian Populations

March 25th 2022

A panel of lung cancer experts from China, South Korea, and Japan share their insights on how they care for their patients with resectable EGFR-positive non–small cell lung cancer.

Cervical Cancer Treatment Paradigm Is Bolstered With Newly Approved Therapies

January 28th 2022

Treatment of patients with metastatic cervical cancer remains challenging—the 5-year overall survival rate is just 17%.

Targeted Therapy Innovator Foresees New Paradigms in Breast Cancer

January 26th 2022

Debu Tripathy, MD, discusses key developments that may set the stage for new directions in care of breast cancer, including several areas of the treatment landscape on the cusp of change.

Investigators Navigate the Complicated Treatment Landscape of Chemotherapy-Induced Neutropenia

January 19th 2022

Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care.

SIMBA Therapy Encounters Barriers But Holds Promise for Neutropenia and Beyond

January 18th 2022

Hope S. Rugo, MD, FASCO, Rita Nanda, MD, William J. Gradishar, MD, and Tiffany A. Traina, MD discuss the selective immunomodulating microtubule-binding agent plinabulin, plus several other novel chemoprotective therapies under exploration, including trilaciclib.

Novel Agents Shake Up Myelodysplastic Syndrome Treatment Landscape

December 27th 2021

During a recent OncLive Peer Exchange®, a panel of hematologic cancer experts shared their insights on the most recent FDA-approved agents for MDS, including luspatercept and decitabine/cedazuridine (Inqovi), both of which were approved in 2020.

Investigators Parse a Crowded Third Line in Relapsed HER2-Positive Metastatic Breast Cancer

December 20th 2021

A panel of breast cancer experts shared their insights on 4 recently approved targeted therapies for patients with relapsed HER2-positive metastatic breast cancer.

Will Slow and Steady Progress in Treating SCLC Win the Race?

October 22nd 2021

Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.

Frontline Treatments for Metastatic RCC March Forward

September 30th 2021

Treatment of metastatic renal cell carcinoma continues to evolve as new regimens steadily receive FDA approval and are added to the armamentarium.

Precision Medicine Paves the Way for Advances in Hormone Receptor–Positive Breast Cancer

September 29th 2021

Early-stage hormone receptor–positive, HER2-negative breast cancer is generally associated with a good prognosis; however, even with early intervention, some patients recur and have reduced survival.

Novel Combos Target Resistance Mechanisms in Advanced Hormone–Driven Breast Cancer

August 26th 2021

Acquired resistance to endocrine therapy has presented challenges for patients with hormone receptor–positive breast cancer.

NTRK- and RET-Targeted Agents Reshape Solid Tumor Landscape

August 5th 2021

Understanding the oncogenic drivers behind a cancer is taking on increasing importance as more effective agents targeting specific gene aberrations continue to emerge.

Transplant-Associated Thrombotic Microangiopathy: New Insights, Emerging Treatments

July 22nd 2021

An expert of panelists provide an overview of TA-TMA, including findings that raise suspicion of this complication, strategies they use for making the diagnosis, and how they intervene given limited treatment options.

New DLBCL Treatments Are Poised to Fill an Unmet Need for Patients in Challenging Settings

May 26th 2021

During a recent OncLive Peer Exchange®, a panel of lymphoma experts discussed tafasitamab-cxix, polatuzumab vedotin-piiq, and selinexor, and how and when they use them for their patients with diffuse large B-cell lymphoma.

Experts Take a Fresh Look at Strategies for Early-Stage HER2+ Breast Cancer

April 5th 2021

Although trastuzumab-based regimens remain the standard treatment for patients with early-stage HER2-positive breast cancer, unanswered clinical questions surround the use of other agents in the neoadjuvant and adjuvant settings.

Frontline ICI Therapy Gains Traction Across NSCLC Settings

March 4th 2021

Treatment strategies for patients with advanced-stage non–small cell lung cancer have shifted away from platinum-based doublet chemotherapy and toward combination strategies that include immune checkpoint inhibitors.

Immuno-Oncology Combinations Dominate in Frontline Treatment of Advanced Clear Cell RCC

February 16th 2021

During a recent OncLive Peer Exchange®, a panel of experts in kidney cancer from the United States and France convened to discuss several important immunotherapy studies presented during the ESMO Virtual Congress 2020, as well as several others that are under way and expected to report out over the next few years.

Systemic Treatment Options Expand in Nonmetastatic NSCLC

February 5th 2021

Although advances in diagnosis and treatment have led to improvements in overall survival for patients with NSCLC, low rates of survival outcomes are present even in those with nonmetastatic disease.